Lilly sues six companies over illegal sales of experimental obesity drug retatrutide

Eli Lilly has filed lawsuits against six companies accused of illegally marketing retatrutide, an experimental obesity drug still in clinical trials. The businesses allegedly sold the drug directly to consumers despite it not yet receiving regulatory approval. Lilly argues the practice poses serious risks to patient safety.